Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Cannabidiol improves symptoms of canine arthritis, study finds
Arthritis affects one in five dogs.

Scientists measure the effect of CBD in dogs diagnosed with the condition. 

Scientists in the United States have discovered that cannabidiol (CBD) can significantly improve the lives of dogs diagnosed with arthritis.

The researchers, from the Baylor College of Medicine in Texas, say their results could pave the way to studying the effects of CBD in humans.

In the study, the scientists first measured the effect of CBD on immune responses associated with arthritis, both in human and murine cells grown in the lab and mouse models. They found that that CBD treatment resulted in reduced production of both inflammatory molecules and immune cells linked to arthritis.

Next, the researchers found that in dogs diagnosed with the condition, CBD treatment significantly improved quality of life as documented by both owner and veterinary assessments. Scientists say their work, published in the journal PAIN, supports future scientific evaluation of CBD for human arthritis.

“We found encouraging results,” said Dr Matthew Halpert, research faculty in the department of pathology and immunology at Baylor. “Nine of the 10 dogs on CBD showed benefits, which remained for two weeks after the treatment stopped. We did not detect alterations in the blood markers we measured, suggesting that, under the conditions of our study, the treatment seems to be safe.”

Arthritis affects one in five dogs, and its prevalence increases as a dog ages, according to Canine Arthritis Management.

Twenty dogs from the Sunset Animal Hospital in Houston were employed for the study. The dogs' owners were given medicine bottles at random, containing either CBD, liposomal CBD, or a placebo. Neither the owner nor the vet knew which treatment each dog was receiving.

The dogs received the treatment each day for four weeks. The vet and the dogs' owners noted the condition of the dogs and whether they noticed any changes in their animal's level of pain, such as changes related to running or gait. The dogs' blood cell count, liver and kidney function were also evaluated before and after treatment.

“We studied dogs because experimental evidence shows that spontaneous models of arthritis, particularly in domesticated canine models, are more appropriate for assessing human arthritis pain treatments than other animal models," said Halpert. "The biological characteristics of arthritis in dogs closely resemble those of the human condition."

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
BSAVA publishes fifth Manual of Canine and Feline Neurology

The BSAVA has published the fifth edition of its BSAVA Manual of Canine and Feline Neurology.

The new edition has been reviewed and updated, including new developments in diagnostics, therapeutic approaches and clinical decision-making. It is structured to support clinicians through diagnosis, treatment and long-term management.

The guide features five new chapters covering acute myelopathies, chronic myelopathies, emergency protocols, neurotoxicology and neuro-oncology.

It also includes over 100 videos, including demonstrations of neurological examinations, clinical presentations and diagnostic procedures.

Nicola Lloyd, publishing manager, said: "Whether you're a general practitioner seeking practical guidance, or a specialist aiming to refine your expertise, this edition remains an indispensable reference for anyone involved in the care of neurologically compromised dogs and cats."